{"analyses":[{"groupDescription":"Treatment comparison between pexidartinib and placebo groups at Week 25","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment comparison analysis","nonInferiorityType":"OTHER","pValue":"0.0019","statisticalMethod":"Mixed effects model for repeated measure"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"2.8"},{"groupId":"OG001","spread":"0.8","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"3.2"},{"groupId":"OG001","spread":"1.0","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"title":"Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"4.1"},{"groupId":"OG001","spread":"1.0","value":"-0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Week 25"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"The Patient-reported Outcomes Measurement Information System (PROMIS) physical function scale was used to assess physical function of the upper and lower limbs. The scale ranged from 1 defined as 'unable to do' or 'cannot do' to 5 defined as 'without any difficulty' or 'not at all', where higher scores represent better outcomes.","dispersionType":"Standard Error","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks Placebo: Placebo capsule matching Pexidartinib capsule for oral administration.","id":"OG001","title":"Placebo Part 1"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Physical function was assessed in the ITT population in participants where data were available.","reportingStatus":"POSTED","timeFrame":"at Week 9 , Week 17, and Week 25","title":"Mean Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function Score in Participants Receiving Pexidartinib Compared With Those on Placebo Up to Week 25","type":"SECONDARY","unitOfMeasure":"units on a scale"}